Jeffrey W. Albers

Director, Spyre Therapeutics, Inc.; Director, Kymera Therapeutics, Inc.

Bought, 12 months

$0.0M

Sold, 12 months

$2.9M

Companies

Latest trade

Aug 7, 2026

Companies

Spyre Therapeutics, Inc.Director −$2.4M Kymera Therapeutics, Inc.Director −$0.7M

Trades

SYRE Sold 23,000 shares at $104.53 · planned $2.4M Aug 7

KYMR Sold 5,000 shares at $89.76 · planned $0.4M Dec 8

KYMR Sold 5,000 shares at $59.19 · planned $0.3M Oct 13

Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.